Literature DB >> 2430055

Increase in the content of quinolinic acid in cerebrospinal fluid and frontal cortex of patients with hepatic failure.

F Moroni, G Lombardi, V Carlà, S Lal, P Etienne, N P Nair.   

Abstract

Quinolinic acid (QUIN), an excitotoxic tryptophan metabolite, has been identified and measured in human cerebrospinal fluid (CSF) using a mass-fragmentographic method. Furthermore, its content has been evaluated in frontal cortex obtained at autopsy from the cadavers of patients who died after hepatic coma. During the coma, the concentration of QUIN in the CSF was 152 +/- 38 pmol ml-1. In contrast, the concentration in control patients affected by different pathologies was 22 +/- 7 pmol ml-1. In the frontal cortex of patients who died after episodes of hepatic encephalopathy, the content of QUIN was three times higher than in controls (2.6 +/- 0.6 versus 0.80 +/- 0.08 nmol/g wet weight). As a result of these investigations we are now able to extend our previous observations on the increase of QUIN in the brains of rats used as experimental models of hepatic encephalopathy to man. QUIN should therefore be added to the list of compounds possibly involved in the pathogenesis and symptomatology of brain disorders associated with liver failure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2430055     DOI: 10.1111/j.1471-4159.1986.tb13071.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

1.  NMDA receptor antagonists prevent acute ammonia toxicity in mice.

Authors:  C Hermenegildo; G Marcaida; C Montoliu; S Grisolía; M D Miñana; V Felipo
Journal:  Neurochem Res       Date:  1996-10       Impact factor: 3.996

2.  Peripheral ammonia as a mediator of methamphetamine neurotoxicity.

Authors:  Laura E Halpin; Bryan K Yamamoto
Journal:  J Neurosci       Date:  2012-09-19       Impact factor: 6.167

3.  Brain quinolinic acid in Alzheimer's dementia.

Authors:  E Sofic; J Halket; A Przyborowska; P Riederer; H Beckmann; M Sandler; K Jellinger
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

Review 4.  Tryptophan, adenosine, neurodegeneration and neuroprotection.

Authors:  T W Stone; C M Forrest; G M Mackay; N Stoy; L G Darlington
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

5.  Oral tryptophan challenge studies in cirrhotic patients: no evidence of neuropsychiatric changes.

Authors:  Andrew Douglass; Hanan Al Mardini; Christopher O Record
Journal:  Metab Brain Dis       Date:  2003-09       Impact factor: 3.584

6.  Loss of [3H]MK801 binding sites in brain in congenital ornithine transcarbamylase deficiency.

Authors:  L Ratnakumari; I A Qureshi; R F Butterworth
Journal:  Metab Brain Dis       Date:  1995-09       Impact factor: 3.584

Review 7.  Cerebrospinal fluid (CSF) analyses in HIV-1 primary neurological disease.

Authors:  J Nogales-Gaete; K Syndulko; W W Tourtellotte
Journal:  Ital J Neurol Sci       Date:  1992-11

8.  Hepatic encephalopathy influences high-affinity uptake of transmitter glutamate and aspartate into the hippocampal formation.

Authors:  W Schmidt; G Wolf; K Grüngreiff; M Meier; T Reum
Journal:  Metab Brain Dis       Date:  1990-03       Impact factor: 3.584

9.  45CaCl2 autoradiography in brain from rabbits with encephalopathy from acute liver failure or acute hyperammonemia.

Authors:  R J de Knegt; J B Gramsbergen; S W Schalm
Journal:  Metab Brain Dis       Date:  1994-06       Impact factor: 3.584

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.